Nicholas Kondo, MD
Cardiovascular Disease · Saratoga Springs, NYNPI 1508834540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 534 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,675 and has fallen 64.1% since, to $601 in 2025.
Across 534 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boehringer Ingelheim$637
- Amgen$627
- Pfizer$615
- Johnson & Johnson$548
- Merck$368
- plus $4K from 31 others
Across 499 payments — averaging $1271.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$591K
- Merck$23K
- Amgen$16K
- Eli Lilly$4K
What the payments were for
- Food & beverage$7,66799%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 140 | $1,233 |
| Boehringer Ingelheim | 39 | $637 |
| Amgen | 39 | $627 |
| Pfizer | 41 | $615 |
| Johnson & Johnson | 47 | $548 |
| Merck | 23 | $368 |
| E.r. Squibb & Sons, L.L.C. | 21 | $334 |
| Novo Nordisk | 18 | $321 |
| Kiniksa Pharmaceuticals, Ltd. | 20 | $321 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $289 |
| AstraZeneca | 19 | $288 |
| Amarin Pharma, Inc. | 16 | $271 |
| Cvrx, Inc. | 3 | $245 |
| Esperion Therapeutics, Inc. | 11 | $222 |
| Kiniksa Pharmaceuticals International, PLC | 12 | $199 |
| Alnylam Pharmaceuticals Inc. | 8 | $172 |
| Bayer | 8 | $160 |
| Sanofi-aventis U.S. LLC | 8 | $146 |
| Arbor Pharmaceuticals, Inc. | 7 | $129 |
| Astellas Pharma US Inc | 2 | $117 |
| Regeneron Healthcare Solutions, Inc. | 6 | $91 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Bridgebio Pharma, Inc. | 3 | $51 |
| Scpharmaceuticals Inc. | 3 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Gilead | 3 | $35 |
| Lundbeck LLC | 2 | $33 |
| Philips North America LLC | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Edwards Lifesciences | 1 | $15 |
| Medtronic | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,781 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 716 | $1,003,686 |
| Repatha SureclickEvolocumab | 282 | $355,834 |
| XareltoRivaroxaban | 148 | $220,042 |
| JardianceEmpagliflozin | 122 | $152,157 |
| FarxigaDapagliflozin Propanediol | 102 | $147,999 |
| EntrestoSacubitril/Valsartan | 61 | $88,193 |
| OzempicSemaglutide | 39 | $40,144 |
| Ezetimibe | 901 | $35,835 |
| Rosuvastatin Calcium | 1,698 | $34,949 |
| Praluent PenAlirocumab | 43 | $32,513 |
| VascepaIcosapent Ethyl | 40 | $28,241 |
| MounjaroTirzepatide | 15 | $22,630 |
| Olmesartan Medoxomil | 658 | $22,314 |
| BrilintaTicagrelor | 17 | $20,927 |
| WegovySemaglutide | 14 | $18,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $615 | $1,003,686716 claims |
| Johnson & JohnsonXarelto | $548 | $220,042148 claims |
| AstraZenecaFarxiga, Brilinta | $288 | $168,926119 claims |
| Boehringer IngelheimJardiance | $637 | $152,157122 claims |
| NovartisEntresto | $1,233 | $88,19361 claims |
| Novo NordiskOzempic, Wegovy | $321 | $58,35353 claims |
| Lilly USA, LLCMounjaro | $23 | $22,63015 claims |
| Esperion Therapeutics, Inc.Nexlizet | $222 | $17,92016 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $129 | $16,49037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Saratoga Springs
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.